Cervical screening is in an unusual position: two different national bodies currently say different things about self-collected testing, so whether it is offered to you depends on which guideline your clinic follows.

Most screening articles give you one set of intervals. Cervical screening cannot honestly be written that way at the moment, because the guidance is mid-transition and the two most-cited sources are not aligned.

Why there are two answers

The U.S. Preventive Services Task Force publishes the recommendation most people have heard of. Its current final cervical screening recommendation dates from 2018. In December 2024 the Task Force issued a draft that would make HPV testing every 5 years the preferred approach for ages 30 to 65 and would, for the first time, include self-collected samples. When the status of that draft was checked on August 11, 2026, it was still published as a draft.

Separately, the Women’s Preventive Services Initiative develops recommendations that the Health Resources and Services Administration adopts as the federal Women’s Preventive Services Guidelines. Those guidelines were updated in January 2026, following a Federal Register notice, and the cervical screening update is exactly the part that changed. The American College of Obstetricians and Gynecologists endorsed the updated guidelines in July 2026, with specific qualifications about self-collection.

This matters practically because clinics follow different guidance. A woman can be told that self-collection “isn’t recommended yet” on the strength of the Task Force draft, while a federally adopted guideline already includes it. Which of the two a given practice has adopted is a question worth asking outright rather than inferring.

What the adopted guidelines say

Cervical screening for average-risk patients under the 2026 Women’s Preventive Services Guidelines, as endorsed by ACOG
Age	Recommended approach
21–29	Cervical cytology alone every 3 years
30–65	Clinician-collected primary high-risk HPV screening every 5 years, using FDA-approved tests for primary screening
30–65, alternative	Co-testing (HPV plus cytology) every 5 years, acceptable when primary HPV testing is unavailable or when the patient chooses it after counselling
30–65, self-collected	Patient-collected primary high-risk HPV screening every 3 years, using FDA-approved tests

Note the interval difference: self-collected screening is recommended every 3 years, not every 5. That is not an oversight — it reflects that the evidence base for self-collected specimens is not identical to clinician-collected, and the shorter interval is the margin built in.

What the Task Force draft found

Even though it remains a draft, the Task Force’s evidence review is worth knowing. Agreement between self-collected vaginal and clinician-collected cervical samples was high, with similar proportions screening positive. Pooled sensitivity of self-collected samples for detecting CIN2+ was 0.86 and specificity 0.81. Across 42 randomised trials comparing self-collection with usual care, 40 found that offering self-collection increased screening rates, with the largest gains among women who had previously been underscreened.

That last finding is the practical case for it: the benefit is largest for people who were not getting screened at all.

Adopted is not the same as covered yet

Three different things are easy to run together, and only the third decides what you are charged.

The recommendation is what the Women’s Preventive Services Initiative wrote and the Health Resources and Services Administration adopted into the federal women’s preventive guidelines. The professional endorsement is what the American College of Obstetricians and Gynecologists said about it, which was a qualified endorsement with reservations specifically about self-collection — a professional body’s view, not a coverage rule. The coverage is a separate legal step with its own clock.

Non-grandfathered health plans must cover the services in the HRSA-supported guidelines without cost sharing, but not from the day a guideline is issued. Under 45 CFR 147.130 the obligation attaches for plan years beginning on or after the date one year after the recommendation or guideline is issued. For a guideline adopted in January 2026, that generally means the first plan year beginning on or after January 2027 — so for many people the coverage change arrives at their next renewal, not now. A plan may adopt it sooner, and some do.

Two practical consequences. A test can be recommended and still be billed to you this year. And if your plan is grandfathered, or is a short-term or non-comprehensive product, the no-cost-sharing rule may not reach it at all. The question worth asking the plan, not the clinic, is which plan year the guideline takes effect in for your coverage.

What to actually ask

Rather than trying to work out which body governs, ask your clinic directly: do you offer self-collected HPV screening, and if so, under which guideline and at what interval? That single question resolves the ambiguity for your own care, and the answer will differ between practices during a transition like this one.

After a hysterectomy

Screening does not automatically stop. It depends on whether the cervix was removed, and on why the surgery was done — a history of a high-grade precancerous lesion (CIN grade 2 or 3) or of cervical cancer changes the answer. Bring the operative report or pathology result; “I had a hysterectomy” alone does not settle it.

Colorectal screening starts at 45

For average-risk adults, colorectal cancer screening begins at 45 rather than the long-familiar 50. This is the most common gap in preventive care for women in their late forties, who often assume it does not yet apply.

More than one test is acceptable. Stool-based tests are done more frequently and need no bowel preparation or sedation; colonoscopy is done at longer intervals and allows polyps to be removed during the same procedure. A positive stool test is not a diagnosis — it is an indication for colonoscopy, and that follow-up is the step most often missed.

Family history moves the start date earlier. A first-degree relative with colorectal cancer or advanced polyps, an inherited syndrome, or inflammatory bowel disease all take a woman out of average-risk screening and into a different plan.

Symptoms are not screening

Bleeding between periods or after intercourse, and rectal bleeding, persistent change in bowel habit, or unexplained iron-deficiency anaemia, are reasons for evaluation when they occur — not reasons to wait for the next scheduled test, and not answered by a normal result from one.

Main takeaway

Patient-collected HPV screening is in the federally adopted women’s preventive guidelines as of January 2026, at a 3-year interval for ages 30 to 65, and ACOG endorsed those guidelines in July 2026 — while the Task Force recommendation containing self-collection was still a draft when this was checked. If you have been told self-collection is not yet recommended, that reflects one source rather than both; ask which guideline your clinic follows. Colorectal screening starts at 45.

Sources

Health Resources and Services Administration — Update to the Women’s Preventive Services Guidelines, Federal Register, January 5, 2026. Records that HRSA published proposed updates on October 1, 2025 relating to cervical cancer screening, developed through the Women’s Preventive Services Initiative, and that the 2025 WPSI evidence review supports primary hrHPV-based screening as the preferred method for ages 30 to 65.
American College of Obstetricians and Gynecologists — Screening for Cervical Cancer, committee statement, July 2026. Source of the age-band table above: cytology alone every 3 years for 21–29; clinician-collected primary hrHPV every 5 years for 30–65 using FDA-approved primary-screening tests; co-testing every 5 years acceptable where primary hrHPV is unavailable or chosen after counselling; and patient-collected primary hrHPV every 3 years.
U.S. Preventive Services Task Force — Cervical Cancer: Screening, the 2018 recommendation, still published as the current final recommendation when checked. Source for the age structure it sets out.
U.S. Preventive Services Task Force — Draft Recommendation: Cervical Cancer: Screening (December 10, 2024), still a draft when checked. Source for the draft’s evidence figures: high agreement between self- and clinician-collected samples, pooled sensitivity 0.86 and specificity 0.81 for CIN2+, and 40 of 42 randomised trials showing increased screening uptake.

Provenance

Status checked, and dated: the Task Force draft was still published as a draft when checked on August 11, 2026. Because guidance here is changing, that check is stated with its date rather than asserted as a permanent fact. An earlier version of this page called the draft status current without checking it, and omitted the adopted guidelines entirely — which would have told a reader self-collection was unavailable when a federally adopted guideline already included it.
Which source governs: the HRSA-adopted Women’s Preventive Services Guidelines and the USPSTF are different instruments with different effects. This page distinguishes them rather than blending them into a single set of intervals.
Route of retrieval: guideline text was obtained through search results rendering the Federal Register, ACOG and Task Force pages, not by direct retrieval of each document. The linked addresses were surfaced by those results.
Colorectal screening: the start age of 45 for average-risk adults is stated from established recommendation. Specific evidence grades and per-test intervals were not re-checked for this article and are deliberately not asserted.

Cervical and Colorectal Cancer Screening for Women